

ESMO Breast Cancer 2025 Industry Satellite Symposium

Friday 16 May 2025 12:15 – 13:15

Room 13

ICM-International Congress Center of the Messe Munich

Overcoming barriers in MBC: Advancing oral SERDs for HR+, HER2- MBC

Time (CEST)	Topic	Speaker
12:15–12:20	Welcome & introduction	Patrick Neven (Belgium)
12:20–12:28	Navigating challenges: Addressing unmet needs in MBC	Patrick Neven (Belgium)
12:28–12:40	From current standards to future innovations: Exploring SERDs in HR+, HER2- MBC	Komal Jhaveri (US)
12:40–12:50	Refining precision: Strategies and best practices for biomarker testing in HR+, HER2- MBC	Ramona Erber (Germany)
12:50–13:15	Views from the clinic: Q&A discussion	All

Objectives

- Appraise the limitations of current endocrine therapies and analyse the evidence for why oral SERDs are needed in patients with HR+, HER2- MBC who progress on endocrine therapy
- Evaluate recent clinical data for current and emerging oral SERDs in patients with HR+, HER2- MBC
- Identify best practices for biomarker testing in the early detection and monitoring of actionable mutations and implications for treatment planning



Patrick Neven
University Hospitals Leuven,
Leuven, Belgium



Komal Jhaveri
Memorial Sloan Kettering
Cancer Center, New York,
NY, USA



Ramona Erber
University of Regensburg,
Regensburg, Germany